Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

WuXi AppTec Co Ltd H (2359)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
35.20 +1.45    +4.30%
26/04 - Closed. Currency in HKD ( Disclaimer )
  • Volume: 9,160,634
  • Bid/Ask: 35.20 / 35.25
  • Day's Range: 33.35 - 35.45
Type:  Equity
Market:  Hong Kong
ISIN:  CNE100003F19 
WuXi AppTec H 35.20 +1.45 +4.30%

WuXi AppTec H Company Profile

 
Read the WuXi AppTec Co Ltd H company profile to learn more about the business and the management team. View WuXi AppTec Co Ltd H facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

43800

Equity Type

ORD

WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People’s Republic of China, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical testing services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.

Contact Information

Address 288 Fute Zhong Road Waigaoqiao Free Trade Zone
Shanghai, 200131
China
Phone 86 21 5046 1111
Fax 86 21 5046 1000

Top Executives

Name Age Since Title
Ge Li 54 2000 Co-Founder, Chairman, President & CEO
Edward Hu 59 2008 Vice Chairman of the Board & Global Chief Investment Officer
Qing Yang 52 2017 Co-CEO & Executive Director
Minzhang Chen 53 2015 Co-CEO & Executive Director
He Liang 56 2017 Chairman of the Supervisory Committee
Shaohua Lu-Wong 54 2007 Independent Non-Executive Director
Feng Dai 47 2018 Independent Non-Executive Director
Wu Yibing 55 2017 Non-Executive Director
Xiaomeng Tong 49 2017 Non-Executive Director
Zhu Minfang 51 2017 Employee Representative Supervisor
Zhiling Zhan - 2023 Independent Non-Executive Director
Wei Yu - 2023 Independent Non-Executive Director
Wu Baiyang 58 2020 Supervisor
Xin Zhang - 2023 Independent Non-Executive Director
Zhaohui Zhang 55 2002 COO of China, VP & Executive Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

2359 Price Commentary

Write your thoughts about WuXi AppTec Co Ltd H
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email